Inventor · disambiguated record
Weimin Qi
Also filed as: QI WEIMIN
9 granted patents·4 pending applications·45 citations·filing 2002–2017
87Inventor score
Top patents by PatentIndex Score
13 records- 0192US9428576B2Anti-p40 antibodies systems and methodsBIOCARE MEDICAL LLC·Filed 2015·Granted Aug 30, 2016·8 cites·13 claims
- 0290US9417243B2Systems and methods for anti-PAX8 antibodiesBIOCARE MEDICAL LLC·Filed 2014·Granted Aug 16, 2016·8 cites·23 claims
- 0388US9708395B2Anti-p40 antibodies systems and methodsBIOCARE MEDICAL LLC·Filed 2016·Granted Jul 18, 2017·5 cites·14 claims
- 0487US8852592B2Systems and methods for anti-PAX8 antibodiesQI WEIMIN·Filed 2012·Granted Oct 7, 2014·10 cites·33 claims
- 0586US9429577B2Anti-uroplakin II antibodies systems and methodsBIOCARE MEDICAL LLC·Filed 2013·Granted Aug 30, 2016·6 cites·12 claims
- 0684US9823251B2Anti-Uroplakin II antibodies systems and methodsBIOCARE MEDICAL LLC·Filed 2016·Granted Nov 21, 2017·3 cites·9 claims
- 0781US9816997B2Anti-SOX10 antibody systems and methodsBIOCARE MEDICAL LLC·Filed 2014·Granted Nov 14, 2017·3 cites·14 claims
- 0878US10295542B2Systems and methods for anti-SOX10 antibodiesBIOCARE MEDICAL LLC·Filed 2017·Granted May 21, 2019·1 cites·15 claims
- 0968US10316103B1Systems and methods for anti-Uroplakin III antibodiesBIOCARE MEDICAL LLC·Filed 2013·Granted Jun 11, 2019·1 cites·4 claims
- 1058US2016370370A1Systems and Methods for Anti-PAX8 AntibodiesBIOCARE MEDICAL LLC·Filed 2016·Application pending·0 cites
- 1157US2005048059A1Therapeutic binding agents against MUC-1 antigen and methods for their useALTAREX INC·Filed 2004·Application pending·0 cites
- 1250US2003194406A1P-cadherin as a target for anti-cancer therapyCHIRON CORP·Filed 2002·Application pending·0 cites
- 1347US2006039915A1P-cadherin as a target for anti-cancer therapyCHIRON CORP·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Weimin Qi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →